Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.

Cancer 2007 May;109(9):1829-35

Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, and Department of Division of Hemato-Oncology, National Health Insurance Corp., Ilsan Hospital, Kyonggi-do, Korea.

Background: The study investigated correlations between adenosine triphosphate / chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-guided platinum-based chemotherapy for unresectable nonsmall-cell lung cancer (NSCLC).

Methods: The authors performed an in vitro chemosensitivity test, ATP-CRA, to evaluate the chemosensitivities of anticancer drugs such as cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, and vinorelbine for chemonaive, unresectable NSCLC. The cell death rate was determined by measuring the intracellular ATP levels of drug-exposed cells compared with untreated controls. A sensitive drug was defined as a drug producing 30% or more reduction in ATP compared with untreated controls. Assay-guided platinum-based 2-drug chemotherapy was given to patients with pathologically confirmed NSCLC.

Results: Thirty-four patients were enrolled. Thirty tumor specimens were obtained by bronchoscopic biopsies and 4 obtained surgically. The median age was 61 years and 27 patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The response rate was 43.8%. At a median follow-up period of 16.9 months, the median progression-free and overall survivals were 3.6 and 11.2 months, respectively. Patients were dichotomized into the platinum-sensitive (S; 20 patients) and resistant (R; 14 patients) groups. The positive/negative predictive values were 61.1% and 78.6% with a predictive accuracy of 68.8%. Although without significant differences in pretreatment parameters, the S-group showed better clinical response (P=.036), longer progression-free survival (P=.060), and longer overall survival (P=.025).

Conclusions: Despite using bronchoscopic biopsied specimens, ATP-CRA and clinical outcomes correlated well after assay-guided platinum-based 2-drug chemotherapy for unresectable NSCLC. There was a favorable response and survival in the platinum-sensitive vs resistant groups.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22601DOI Listing
May 2007
53 Reads

Publication Analysis

Top Keywords

2-drug chemotherapy
12
chemotherapy unresectable
12
platinum-based 2-drug
12
untreated controls
8
unresectable nsclc
8
compared untreated
8
lung cancer
8
clinical outcomes
8
nonsmall-cell lung
8
unresectable nonsmall-cell
8
atp-cra clinical
8
atp-cra-guided platinum-based
8
assay-guided platinum-based
8
response assay
8
chemotherapy response
8
chemotherapy
6
patients
6
response
5
drug defined
4
clinical response
4

References

(Supplied by CrossRef)

Hoffman et al.
Lancet. 2000

Von Hoff et al.
J Natl Cancer Inst. 1990

Wilbur et al.
Br J Cancer. 1992

Shaw et al.
J Cell Biochem Suppl. 1996

Xu et al.
Breast Cancer Res Treat. 1999

Kurbacher et al.
Anticancer Drugs. 1998

Loizzi et al.
Am J Obstet Gynecol. 2003

Maenpaa et al.
Gynecol Oncol. 1995

Cree et al.
Anticancer Drugs. 1997

Sharma et al.
BMC Cancer. 2003

Kawamura et al.
Eur J Cancer. 1997

Similar Publications